Mechanism

TrialResults-center.org

Menu

relaxine

Serelaxin

heart failure, in acute heart failure

Endpoint	TE [95% CI]	p val	I2	n	k
death or hospitalization	no data
Cardiovascular death or hospital admission for CHF	no data
heart failure death	no data
hospitalisation for cardiovascular causes	no data
CV death, MI hospitalization for HF	no data
Cardiovascular death	no data
hospitalisation for heart failure	no data
All cause death	no data

Trial	Studied treatment	Control	Patients
Pre-RELAX-AHF, 2009	intravenous relaxin for 48 hours: 10µg/kg daily, 30µg/kg daily, 100µg/kg daily, 250µg/kg daily	placebo	Patients hospitalized with acute heart failure

Modal title

- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy -